AVAVA™ Announces the Launch of MIRIA™ at ASLMS 2024 the Energy-Based Medicine & Science Conference
AVAVA™, an innovative aesthetics company focused on becoming a portal to the future of skin vitality, today announces the official launch of MIRIA™ by AVAVA. In addition, through an exclusive distribution partnership with Jeisys, MIRIA will be available in Korea…
Servier Receives Regulatory Filing Acceptances from FDA and EMA for Vorasidenib in the Treatment of IDH-Mutant Diffuse Glioma
Servier, a global leader in oncology focused on delivering meaningful therapeutic progress for the patients it serves, today announced the FDA filing acceptance and priority review for a New Drug Application (NDA) for vorasidenib, as well as the EMA granting…
ChemDiv Helps Advance Viriom’s Influenza Treatment to Successful Phase I Clinical Trials Completion
ChemDiv Inc., dedicated to partnering in discovery and development of breakthrough therapies based on its unique chem-bio platforms, announces successful completion of Phase I clinical trials for AV5124, an innovative influenza virus replication inhibitor being developed by Viriom Inc. (Viriom)….
